ReviewCurrent opinion in microbiology2026
Advances in biocontainment strategies of engineered microbes for use in humans.
Review in Current opinion in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogenesis of Micro/Nanoplastics in Mammalian Systems: Gut to Systemic Multi-Organ Dysfunction.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genetically engineered microorganisms have been designed for use in many aspects of medicine. Advances in synthetic biology allow for the design of these organisms for a wide number of uses in a variety of environments. However, these advances are accompanied by the need for robust biocontainment strategies to prevent unwanted colonization and dissemination of engineered microorganisms. In this review, we discuss the current state of biocontainment strategies for use in biomedical applications. Many biocontainment strategies exist, including toxin-antitoxin systems, kill switches, auxotrophy, CRISPR-based targeted DNA degradation, nonstandard amino acids, and physical barriers. We discuss the use and caveats of these strategies both alone and in combination with each other. Additionally, we discuss the use and efficacy of these strategies in clinical trials. Finally, we discuss the need for standardized testing of containment escape. As use of these engineered microorganisms progresses, it is paramount that containment strategies advance with them to ensure safety, minimize environmental impact, and maintain a positive public view of this important work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.